These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 36797979)

  • 21. Role of postmarketing surveillance in contemporary medicine.
    Woodcock J; Behrman RE; Dal Pan GJ
    Annu Rev Med; 2011; 62():1-10. PubMed ID: 20809798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Food and Drug Administration Adverse Event Reports of Retinal Vascular Occlusions Associated With Phosphodiesterase Type 5 Inhibitor Use.
    Li AS; Pomeranz HD
    J Neuroophthalmol; 2016 Dec; 36(4):480-481. PubMed ID: 27851718
    [No Abstract]   [Full Text] [Related]  

  • 23. Impact of United States Food and Drug Administration's boxed warnings on adverse drug reactions reporting rates and risk mitigation for multiple myeloma drugs.
    Garg V; Raisch DW; McKoy JM; Trifilio SM; Holbrook J; Edwards BJ; Belknap SM; Samaras AT; Nardone B; West DP
    Expert Opin Drug Saf; 2013 May; 12(3):299-307. PubMed ID: 23480866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of completeness for spontaneous reporting of disease-modifying therapies in multiple sclerosis.
    Araujo AGS; Lucchetta RC; Tonin FS; Pontarolo R; Borba HHL; Wiens A
    Expert Opin Drug Saf; 2021 Jun; 20(6):735-740. PubMed ID: 33641547
    [No Abstract]   [Full Text] [Related]  

  • 25. Adverse drug reactions and reporting.
    Witte R
    Clin J Oncol Nurs; 2000; 4(4):181, 184. PubMed ID: 11261100
    [No Abstract]   [Full Text] [Related]  

  • 26. Postmarketing safety surveillance of trivalent recombinant influenza vaccine: Reports to the Vaccine Adverse Event Reporting System.
    Woo EJ; Moro PL; Cano M; Jankosky C
    Vaccine; 2017 Oct; 35(42):5618-5621. PubMed ID: 28886946
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS).
    Rahman MM; Alatawi Y; Cheng N; Qian J; Peissig PL; Berg RL; Page DC; Hansen RA
    Clin Drug Investig; 2017 Dec; 37(12):1143-1152. PubMed ID: 28933038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pilot projects to stimulate adverse drug reaction reporting.
    Fincham JE
    J Clin Pharm Ther; 1987 Aug; 12(4):243-7. PubMed ID: 3624325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of the impact of scheduled postmarketing safety summary analyses on regulatory actions.
    Sekine S; Pinnow EE; Wu E; Kurtzig R; Hall M; Dal Pan GJ
    Clin Pharmacol Ther; 2016 Jul; 100(1):102-8. PubMed ID: 26853718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reporting drug side effects: signals and noise.
    Avorn J
    JAMA; 1990 Apr; 263(13):1823. PubMed ID: 2313853
    [No Abstract]   [Full Text] [Related]  

  • 31. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
    Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
    Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MedWatch targets reporting of serious adverse events.
    VanAmringe M
    Jt Comm Perspect; 1993; 13(4):15. PubMed ID: 10129237
    [No Abstract]   [Full Text] [Related]  

  • 33. Strategy for surveillance of adverse drug events.
    Bright RA
    Food Drug Law J; 2007; 62(3):605-16. PubMed ID: 17915403
    [No Abstract]   [Full Text] [Related]  

  • 34. The prescription drug user fee act: active postmarketing drug surveillance and safety.
    Lyles A
    Clin Ther; 2002 May; 24(5):800-2. PubMed ID: 12075947
    [No Abstract]   [Full Text] [Related]  

  • 35. Reverse translation of adverse event reports paves the way for de-risking preclinical off-targets.
    Maciejewski M; Lounkine E; Whitebread S; Farmer P; DuMouchel W; Shoichet BK; Urban L
    Elife; 2017 Aug; 6():. PubMed ID: 28786378
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems.
    Kessler DA
    J Am Podiatr Med Assoc; 1994 Jan; 84(1):35-8. PubMed ID: 8295131
    [No Abstract]   [Full Text] [Related]  

  • 37. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).
    Shimabukuro TT; Nguyen M; Martin D; DeStefano F
    Vaccine; 2015 Aug; 33(36):4398-405. PubMed ID: 26209838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccine adverse event reporting: the importance of follow-up.
    Varricchio F
    Expert Rev Vaccines; 2005 Aug; 4(4):445-8. PubMed ID: 16117700
    [No Abstract]   [Full Text] [Related]  

  • 39. Xyrem (sodium oxybate) postmarketing adverse event reporting system.
    Wang YG
    Sleep Med; 2010 Jun; 11(6):595; author reply 595-6. PubMed ID: 20362501
    [No Abstract]   [Full Text] [Related]  

  • 40. Monitoring adverse drug events: the Food and Drug Administration MedWatch reporting system.
    Landow L
    Reg Anesth Pain Med; 1998; 23(6 Suppl 2):190-3. PubMed ID: 9845393
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.